Accelerating Rare Disease Clinical Trials: Asia-Pacific Expedited Review Pathways

Introduction: The Growing Importance of Asia-Pacific in Rare Disease Trials

As global pharmaceutical companies expand clinical research into emerging markets, the Asia-Pacific (APAC) region has gained increasing relevance in rare disease trials. Several countries in APAC—including Japan, South Korea, Australia, Singapore, and China—have introduced expedited review mechanisms to facilitate the development and approval of therapies for orphan and ultra-rare conditions. These programs aim to address unmet medical needs by shortening regulatory timelines and improving trial feasibility in diverse populations.

Understanding the key differences in APAC regulatory pathways is critical for sponsors conducting multi-country rare disease trials or seeking early market entry. This article outlines the major expedited programs in the region and offers strategic insights for regulatory planning.

Japan: Sakigake and Conditional Early Approval (CEA)

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) offers two expedited programs particularly relevant to rare disease developers:

• Sakigake Designation: For innovative therapies addressing serious diseases with high unmet needs. Sponsors benefit from PMDA consultation, prioritized review, and reduced approval timelines.
• Conditional Early Approval (CEA): Permits marketing of a drug based on early-phase clinical data if efficacy and safety can be reasonably expected. Post-marketing studies are required to confirm benefit-risk.

Both programs are applicable to orphan drugs, especially those targeting rare cancers, genetic disorders, and pediatric indications. Japan also offers regulatory consultation and fast-track status for designated orphan products.

South Korea: Expedited Approval by MFDS

South Korea’s Ministry of Food and Drug Safety (MFDS) operates a Fast-Track Designation System for rare diseases under the Pharmaceutical Affairs Act. Key features include:

• Reduced clinical trial duration requirements
• Priority review for Investigational New Drug (IND) and New Drug Application (NDA) submissions
• Rolling review for certain sections of the dossier

MFDS also provides customized consultation services for sponsors developing products for rare pediatric conditions and ultra-orphan diseases.

Australia: TGA Priority Review and Provisional Approval

The Therapeutic Goods Administration (TGA) in Australia offers two expedited options:

• Priority Review: For life-threatening or seriously debilitating diseases, including rare conditions. Approval in 150 working days instead of 255.
• Provisional Approval: Based on early clinical data; valid for 2 years with possible extensions. Requires confirmatory evidence post-approval.

Both pathways are frequently used by sponsors of gene therapies, enzyme replacement products, and targeted treatments for rare neurological disorders.

External Resource

Visit the Australia and New Zealand Clinical Trials Registry (ANZCTR) to explore ongoing rare disease studies in the region.

Singapore: Special Access Routes and Expedited Review

The Health Sciences Authority (HSA) in Singapore operates a Priority Review Scheme for new chemical entities addressing rare or serious conditions. Features include:

• Target review time: 120 days (vs. standard 270)
• Accelerated clinical trial authorization for local studies
• Bridging data acceptance from foreign regulatory authorities (e.g., FDA, EMA)

Additionally, the Special Access Route (SAR) allows compassionate use of unregistered therapies in life-threatening cases, relevant for ultra-rare disorders with no local treatments.

China: Conditional Approval and Breakthrough Designation

China’s National Medical Products Administration (NMPA) has implemented progressive reforms to support rare disease drug development. Notable mechanisms include:

• Breakthrough Therapy Designation (BTD): For drugs showing significant early clinical benefit. Offers rolling review, multi-round agency engagement, and shortened approval timelines.
• Conditional Approval: Grants marketing based on Phase II data for urgent public health needs, with post-approval requirements.

China also maintains a rare disease list (121 conditions as of latest update), and inclusion enhances regulatory priority for trial approval and data review.

Harmonization Efforts in ASEAN and APEC

Efforts to harmonize regulatory processes for rare diseases are ongoing under regional frameworks:

• ASEAN Common Technical Dossier (ACTD): Enables consistent submission format across Southeast Asian countries.
• Asia-Pacific Economic Cooperation (APEC): Supports regulatory convergence and capacity-building for rare disease product evaluation.

Participation in pilot programs like the APEC Regulatory Harmonization Steering Committee offers opportunities for early dialogue and cross-border trial facilitation.

Strategic Considerations for Sponsors

To leverage expedited pathways in APAC, sponsors should:

• Engage local regulatory consultants with in-depth knowledge of national programs
• Sequence submissions to align with agency-specific review timelines
• Incorporate region-specific clinical endpoints and local epidemiology data
• Prepare for ethics committee and hospital-level approvals, which may vary by country

Cross-functional regulatory planning—including coordination with CROs, investigators, and legal teams—is essential for multi-country execution.

Conclusion: Asia-Pacific as a Strategic Opportunity in Rare Disease Development

Asia-Pacific’s diverse regulatory landscape offers both challenges and opportunities. With increasing rare disease awareness, more APAC countries are aligning with global standards while also providing unique incentives and fast-track options.

Sponsors who proactively study and integrate these pathways into their development strategy can shorten time to trial initiation, gain early market access, and provide life-saving therapies to patients with high unmet medical needs across the region.